The conjugate enthusiasm bypasses Mythic
The private ADC company is being wound down.
Syndax switches first-line plans
In fit KMT2Ar patients the group will focus on Revuforj plus Venclexta and azacitidine.
Corcept tries to repeat the glucocorticoid trick
Nenocorilant features among the latest industry projects newly into phase 1.
Lung toxicity deaths halt ifinatamab
Ideate-Lung02 goes on global clinical hold.
Enhertu completes its front-line march
Astra and Daiichi bag FDA approval based on Destiny-Breast09.
BeOne starts another front-line sonrotoclax fight
The new phase 3 trial, in first-line CLL, is expected to begin in January 2026.
Henlius and Ottimo join the bispecific bundle
Two new PD-(L)1 x VEGF projects have entered the clinic.
Ringside sends Immunome towards filing
On a cross-trial basis varegacestat beats Ogsiveo.
